NEXGEL appoints two Sequence LifeScience leaders to board; Sequence led $5.5M financing

NEXGEL, INC.

Brian J. Kieser (CEO) and Kevin M. Harris (COO) of Sequence LifeScience appointed to NEXGEL board effective May 6, 2026.
Sequence led $5.5M convertible note financing ($0.60/ share conversion, $0.80 warrant) to close Celularity acquisition.
Kieser individually issued $1M convertible note (same terms: $0.60 conversion, $0.80 warrant) on May 11, 2026.
Kieser is indirect sole owner of Sequence; Harris is COO with no equity in Sequence.

item 5.02item 8.01item 9.01

Source: SEC EDGAR

accession 0001493152-26-022503

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.